1. Home
  2. YI vs ANVS Comparison

YI vs ANVS Comparison

Compare YI & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 111 Inc.

YI

111 Inc.

HOLD

Current Price

$3.58

Market Cap

38.1M

ML Signal

HOLD

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$4.53

Market Cap

53.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YI
ANVS
Founded
2010
2008
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.1M
53.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
YI
ANVS
Price
$3.58
$4.53
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$13.50
AVG Volume (30 Days)
11.3K
4.0M
Earning Date
12-05-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,979,883,442.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.19
$1.11
52 Week High
$11.35
$6.37

Technical Indicators

Market Signals
Indicator
YI
ANVS
Relative Strength Index (RSI) 38.01 64.94
Support Level $3.60 $4.12
Resistance Level $3.95 $4.82
Average True Range (ATR) 0.22 0.54
MACD 0.04 -0.01
Stochastic Oscillator 51.22 53.78

Price Performance

Historical Comparison
YI
ANVS

About YI 111 Inc.

111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.

About ANVS Annovis Bio Inc.

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

Share on Social Networks: